secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIPELLA PHARMACEUTICALS INC. (LIPO)
CIK:        0001347242
Form:       8-K
Filed at:   2024-12-10T23:59:59+00:00
Accession:  0001753926-24-002052
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipella Pharmaceuticals enters agreement for up to $6M Series B convertible preferred offering
--------------------------------------------------------------------------------

- Offering of up to $6,000,000 in Series B non-voting convertible preferred stock; underwritten by Spartan Capital Securities.
- Placement agent fee: 10% of gross proceeds in cash plus warrants for 10% of conversion shares at $1.00/share, 5-year term.
- Separate consulting agreement with Spartan: $300,000 cash fee and 700,000 shares of Series C Preferred Stock for advisory services.
- Series C Preferred Stock is junior to other preferred, pari passu with common, convertible 1:1 with 4.99% beneficial ownership limit.
- Investors granted right to purchase additional $6M in a Mirror Offering within six months of registration effective date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347242/000175392624002052/0001753926-24-002052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347242/000175392624002052/g084587_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-24-002052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer